• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Malkani Dhiraj H

    7/6/26 4:37:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KNSA alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Malkani Dhiraj H

    (Last)(First)(Middle)
    C/O KINIKSA PHARMACEUTICALS INT'L
    105 PICCADILLY, SECOND FLOOR

    (Street)
    LONDONW1J 7NJ

    (City)(State)(Zip)

    UNITED KINGDOM

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/29/2026
    3. Issuer Name and Ticker or Trading Symbol
    Kiniksa Pharmaceuticals International, plc [ KNSA ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    CHIEF STRATEGY OFFICER
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Douglas Barry, Attorney-in-Fact07/06/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $KNSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KNSA

    DatePrice TargetRatingAnalyst
    2/19/2026$62.00Buy
    Canaccord Genuity
    9/29/2025$60.00Buy
    TD Cowen
    3/13/2025$40.00Buy
    Citigroup
    9/13/2024$40.00Buy
    Jefferies
    5/3/2024$34.00Overweight
    Wells Fargo
    12/29/2021$37.00 → $34.00Buy
    B of A Securities
    More analyst ratings

    $KNSA
    SEC Filings

    View All

    Kiniksa Pharmaceuticals International plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)

    5/29/26 4:35:27 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Kiniksa Pharmaceuticals International plc

    SCHEDULE 13D/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    5/26/26 5:04:50 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals International plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)

    5/26/26 4:55:02 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

    LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in fireside chats at the following investor conferences in June: 2026 Jefferies Global Healthcare Conference on Wednesday, June 3 at 8:45 a.m. Eastern TimeGoldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9 at 11:20 a.m. Eastern Time A live webcast of Kiniksa's presentations will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. A replay of the events will also be available on Kiniksa's website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharm

    5/29/26 4:01:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $930 - $945 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to initiate by year-end –– Q1 2026 cash balance increased to $468.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 28, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today r

    4/28/26 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

    LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and reg

    4/23/26 4:01:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CHIEF STRATEGY OFFICER Malkani Dhiraj H

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    7/6/26 4:42:47 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Malkani Dhiraj H

    3 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    7/6/26 4:37:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Quart Barry D converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    6/2/26 4:52:27 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Kiniksa Pharmaceuticals with a new price target

    Canaccord Genuity initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $62.00

    2/19/26 7:51:41 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Kiniksa Pharmaceuticals with a new price target

    TD Cowen initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $60.00

    9/29/25 9:58:02 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Kiniksa Pharmaceuticals with a new price target

    Citigroup initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    3/13/25 7:43:42 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Financials

    Live finance-specific insights

    View All

    Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $930 - $945 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to initiate by year-end –– Q1 2026 cash balance increased to $468.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 28, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today r

    4/28/26 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

    LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and reg

    4/23/26 4:01:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by the end of 2026 –– Cash balance increased by $170.4 million in 2025 to $414.1 million –      – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE) --  – Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus

    2/24/26 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/14/24 4:32:31 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/14/24 4:15:22 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/13/24 4:30:25 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care